Ultralight, an electronic health records company focused on longevity and personalized medicine clinics, has raised $9.3 million in pre-seed and seed funding, CEO Sunita Mohanty told Axios Pro exclusively. The money is now in the hands of a private company building software for a niche corner of the healthcare market, while the clinics and patients it serves remain inside a system where access, data, and care are all mediated by corporate platforms.
Who Gets the Money
The company’s pitch is straightforward: Ultralight develops electronic health records tailored for longevity and personalized medicine clinics. That means the infrastructure of care is being shaped by a startup with fresh venture backing, not by patients or clinicians organizing their own tools from the ground up. The $9.3 million in pre-seed and seed funding gives the company runway to keep building that platform.
CEO Sunita Mohanty told Axios Pro exclusively about the raise, making the funding itself the headline event. The article does not say who provided the money, only that the company secured it. In the usual hierarchy of health tech, that leaves the people actually using the system at the bottom while investors and executives decide what gets built, when, and for whom.
What the Company Is Building
Ultralight is focused on electronic health records for longevity and personalized medicine clinics. Those clinics sit in a specialized slice of healthcare, and Ultralight is positioning itself as the software layer for that niche. The company’s work is described in the article as an EHR platform, which means it is part of the digital apparatus that organizes records, workflows, and access inside clinics.
The article gives no clinical validation, no market performance data, and no patient outcomes. What it does give is a funding milestone and a timeline. Ultralight plans to raise its Series A in 2027. That future round is the next checkpoint in the familiar venture pipeline: raise money, build product, raise more money, and keep the whole machine moving according to investor expectations.
The Funding Track Ahead
The planned Series A in 2027 suggests the company is still in the early stages of its climb through the startup funding ladder. For now, the $9.3 million pre-seed and seed round is the main fact on the table. It signals investor interest in specialty healthcare IT tied to longevity and personalized medicine clinics, but it does not tell patients anything about whether the software will make care more accessible, more transparent, or less controlled by the usual corporate gatekeepers.
Ultralight’s focus on longevity and personalized medicine clinics also places it inside a broader healthcare economy where premium services and data systems are often built for those who can pay, while everyone else gets the leftovers. The article does not spell out those dynamics, but it does show the basic arrangement: a startup, a funding round, and a plan to keep climbing.
Sunita Mohanty’s exclusive disclosure to Axios Pro is the only direct quote or public statement in the article. The rest is the quiet language of capital: a company raises money, announces a future round, and moves on. The clinics may be about longevity, but the business model is pure startup survival.